NCT07416474

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Randomized, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 574 (estimated)
• Sponsor: RemeGen Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	RC148 plus Carboplatin and Paclitaxel	RC148, Carboplatin, Paclitaxel
DRUG	Tislelizumab plus Carboplatin and Paclitaxel	Tislelizumab, Carboplatin, Paclitaxel

Timeline

• Start date: 2026-03-31
• Primary completion: 2027-12-31
• Completion: 2029-11-30
• First posted: 2026-02-18
• Last updated: 2026-02-20

Locations

66 sites across 1 country: China